top of page

EHA 2026: Nurix Therapeutics' CEO Arthur Sands discusses this week's big collaboration deal with Roche, and highlights the company's EHA data and broader platform

  • Jun 12
  • 1 min read

He says he believes the Roche deal is an important transaction for the entire field of degraders. Plus, discussing antibody-degrader conjugates and an update on the company's immunology programs as well.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page